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1. Introduction 
Vocal cord paralysis can occur as a result of injury to the recurrent laryngeal nerve (RLN). 
Possible causes include iatrogenic surgical injury (cardiac, thoracic, neck), neoplasm (e.g. 
thyroid, esophagus, lung) or neurological disease. Injury to the RLN results in vocal cord 
paresis or paralysis. Poor or absent movement of one or both vocal folds causes difficulties 
with voice, swallowing or breathing. This can have a substantial negative effect on quality of 
life due to poor vocal function, aspiration, and upper airway obstruction in the rare event of 
bilateral RLN injury.  
2. Anatomy of the recurrent laryngeal nerve 
Injury to the RLN can occur at any point along the course of the nerve, which spans the neck 
and thorax. The RLN is a branch of the vagus nerve, and has an extensive and complex 
anatomical course, beginning at the brainstem, coursing through the skull base, within the 
carotid sheath in the neck, into the thorax, looping around the aortic arch (left RLN), around 
the subclavian artery (right RLN), within the tracheoesophageal groove, posteromedial to 
the thyroid gland, and enters the larynx at the posteroinferior border of the cricoid cartilage. 
The RLN provides motor supply to the thyroarytenoid muscle, posterior cricoarytenoid 
muscle, lateral cricoarytenoid muscle, and interarytenoid muscles. It also provides sensory 
supply to the glottis and infraglottic larynx. 
3. Current management options for unilateral vocal cord paralysis 
Standard options for management of unilateral vocal cord paralysis include observation, 
voice and swallowing therapy, and surgery.  
www.intechopen.com
 
Gene Therapy Application 
 
424 
4. Observation 
Patients sometimes exhibit variable clinical improvement with expectant management. This 
can be due to (i) spontaneous nerve regeneration, or (ii) natural compensation for glottic 
insufficiency by strengthening of the contralateral vocal cord. 
5. Voice and swallowing therapy 
A referral to an experienced speech language pathologist is commonly employed in cases of 
severe functional deficit where patients are reluctant or unfit to pursue surgery. Voice and 
swallowing rehabilitation has been shown to be effective, especially in motivated patients. 
6. Surgery 
Medialization of the paralyzed vocal cord aims to close the glottic gap, resulting in 
improvement in voice and aspiration. Specific procedures can be classified into 
endolaryngeal and extralaryngeal. Endolaryngeal procedures include injection 
laryngoplasty, whereby a ‘filler’ substance is injected into the paraglottic space, either 
percutaneously or endoscopically. Percutaneous approaches are performed in the clinic as 
an office-based procedure, and can be done safely under endoscopic guidance with local 
anaesthesia transorally, through the thyrohyoid membrane, through the thyroid cartilage, or 
most commonly, through the cricothyroid membrane. “Filler” substances commonly 
employed include calcium hydroxyapatite, collagen, and autologous fat. Extralaryngeal 
procedures include medialization laryngoplasty (thyroplasty), arytenoid adduction, and 
cricothyroid subluxation with adduction arytenopexy. The most commonly performed 
extralaryngeal procedure is the medialization thyroplasty. This is done in the operating 
room with IV sedation. The laryngeal framework is approached transcervically, and an 
alloplastic implant (such as Gortex™ or silastic) is inserted into the paraglottic space after 
drilling a window through the thyroid cartilage. This operation can be safely performed as 
an outpatient in selected patients (Zhao et al., 2010). Although implants can be hand-carved, 
contemporary thyroplasty systems include fully or partially pre-fabricated implants with 
gender-specific sizers and templates, for improved technical precision. 
7. Pitfalls and shortcomings of current therapies 
Although current therapies have been shown to be clinically effective, they represent static 
solutions to a dynamic problem. Physiologic vocal cord function is not actually restored. 
The ability to restore physiologic vocal cord movement depends upon developing strategies 
to maintain survival of injured or vulnerable neurons and to stimulate axonal regeneration 
to appropriate laryngeal muscles (Hogikyan et al. 2001, Rubin et al. 2003). 
8. Nerve regeneration 
Spontaneous natural nerve recovery can occur, but axon regrowth may fail to reach the 
laryngeal muscles, or fail to reinnervate the correct muscles (Crumley et al. 2000). Non-
selective reinnervation of adductor and abductor laryngeal muscles results in synkinesis, 
which explains the variable clinical outcomes observed with expectant management. 
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It is known that neurotrophic and neuroprotective growth factors can prevent nerve 
degeneration following injury. Administration of these growth factors through the central 
nervous system (CNS) is an appealing strategy. However, technical access to these 
neurons is challenging, and direct injection is ineffective, since trophic factors diffuse 
poorly, and can cause injury to adjacent neuronal structures. A novel and innovative 
approach that is minimally invasive and avoids systemic side effects is remote delivery 
utilizing a viral vector, and forms the fundamental basis of the emerging evidence from 
investigations into the potential role of gene therapy for treatment of recurrent laryngeal 
nerve injury. 
9. Gene therapy – a promising novel strategy for treatment of RLN injury 
The remote delivery of genes encoding therapeutic growth factors to the CNS is an attractive 
management strategy, because it avoids the potential pitfalls of direct CNS injection (into 
the brainstem or spinal cord) and systemic administration. In this approach, viral vectors 
can be injected into the peripheral nervous system and be transported in a retrograde 
fashion to the CNS (Boulis et al. 1999, Rubin et al. 2001). Several viral vectors have been 
described for in vivo gene transfer in the nervous system, including herpes simplex virus, 
retroviruses, adenovirus, and adeno-associated virus (AAV). Contemporary bench 
techniques can impact virus attenuation, thereby preventing the negative consequences of 
local proliferation, and allow the addition of potentially therapeutic genes.  
Previous research by our group has shown that an AAV vector, remotely injected into the 
RLN, travels in a retrograde fashion to the rat brainstem (Rubin et al. 2001) and that 
injection of an adenoviral vector into a crushed RLN added no additional injury compared 
with crush alone (Shiotani et al. 1999). 
An experimental model of RLN injury for the study of viral gene therapy has been 
previously described (Fung et al., 2008, Figure 1). In this model, a standardized crush injury 
was induced to the RLN. Immediately following crush, there was a dramatic, measurable 
decrease in nerve–endplate contact percentage, and spontaneous recovery was observed by 
three weeks post-injury. Recovery was confirmed both endoscopically as well as 
histologically by determining a high nerve-endplate contact percentage. Nerve-endplate 
contact was quantified by a rigorous method of evaluation of immunohistochemically 
stained rat larynges for neurofilament and motor endplates. We showed that this method 
reliably quantified the anatomical integrity of neuromuscular connections in laryngeal 
muscle.  
There are promising results from a study (Sabowski et al., 2009) investigating the effects of 
remote administration of an engineered zinc-finger protein transcription factor, Ad-32Ep65-
Flag (Ad-p65). This factor has been found to induce expression of vascular endothelial 
growth factor (VEGF; also called VEGF-A). VEGF has well known neuroprotective effects. 
Subsequent work demonstrated that remote injection of Ad-p65 after RLN crush accelerated 
the return of vocal fold mobility and the percentage of nerve-endplate contacts in the 
thyroarytenoid muscle. Similar results have been described with adenoviral GDNF gene 
transfer (Araki et al., 2006). This study observed faster motor nerve conduction velocity of 
the RLN and quicker recovery rate of vocal fold movement following gene transfer. 
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*reproduced from Fung et al. (2008) 
Fig. 1. 
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Reproduced from Fung et al. (2008) 
Fig. 2. (A) Dennervation, as evidenced by low neuron-motor endplate contact percentage, 
following crush injury. 
(B) Reinnervation, as evidence by high neuron-motor endplate contact percentage, following 
3 weeks of recovery. 
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10. Conclusion 
Gene therapy is a promising methodology that may enhance our ability to minimize nerve 
injury while maximizing functional outcome. Research using this model to investigate the 
potential therapeutic role of viral gene therapy for the treatment of recurrent laryngeal 
nerve injury is ongoing. 
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